BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Return
64.18%
This Quarter Return
+11.67%
1 Year Return
+64.18%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$147M
AUM Growth
-$56.7M
(-28%)
Cap. Flow
-$64.4M
Cap. Flow
% of AUM
-43.88%
Top 10 Holdings %
Top 10 Hldgs %
58.43%
Holding
30
New
9
Increased
3
Reduced
8
Closed
10
Top Buys
| 1 |
Qiagen
QGEN
|
+$7.31M |
| 2 |
Smith & Nephew
SNN
|
+$6.97M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$6.74M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$6.68M |
| 5 |
Brookdale Senior Living
BKD
|
+$6.62M |
Top Sells
| 1 |
Biogen
BIIB
|
+$12.7M |
| 2 |
Globus Medical
GMED
|
+$11.8M |
| 3 |
QGENF
QIAGEN NV
QGENF
|
+$11.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$10.9M |
| 5 |
BCR
CR Bard Inc.
BCR
|
+$9.3M |
Sector Composition
| 1 | Healthcare | 89.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSRO
1
DELISTED
TESARO, Inc.
TSRO
| $9.44M | 6.43% |
67,490
-17,159
| -20% | -$2.4M |
|
|
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.28M | 6.32% |
99,101
-50,899
| -34% | -$4.77M |
|
3
Incyte
INCY
$16.2B
| $9.07M | 6.18% |
72,051
+2,373
| +3% | +$299K |
|
4
Ironwood Pharmaceuticals
IRWD
$213M
| $8.87M | 6.05% |
561,180
-244,770
| -30% | -$3.87M |
|
|
WMGI
5
DELISTED
Wright Medical Group Inc
WMGI
| $8.81M | 6% |
320,420
+14,255
| +5% | +$392K |
|
6
BioMarin Pharmaceuticals
BMRN
$10.4B
| $8.58M | 5.85% |
94,454
-10,546
| -10% | -$958K |
|
|
PRAH
7
DELISTED
PRA Health Sciences, Inc.
PRAH
| $7.99M | 5.45% |
106,555
-33,445
| -24% | -$2.51M |
|
8
Edwards Lifesciences
EW
$45.5B
| $7.95M | 5.42% |
201,798
-68,202
| -25% | -$2.69M |
|
|
ABMD
9
DELISTED
Abiomed Inc
ABMD
| $7.94M | 5.41% |
55,387
-19,613
| -26% | -$2.81M |
|
|
NVRO
10
DELISTED
NEVRO CORP.
NVRO
| $7.82M | 5.33% |
105,000
+5,000
| +5% | +$372K |
|
|
11
Qiagen
QGEN
$9.82B
| $7.31M | 4.98% |
+205,543
| New | +$7.31M |
|
|
12
Smith & Nephew
SNN
$16.4B
| $6.97M | 4.75% |
+200,000
| New | +$6.97M |
|
|
PTLA
13
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.74M | 4.59% |
+120,000
| New | +$6.74M |
|
|
14
Neurocrine Biosciences
NBIX
$14.1B
| $6.68M | 4.55% |
+145,303
| New | +$6.68M |
|
|
15
Brookdale Senior Living
BKD
$1.78B
| $6.62M | 4.51% |
+450,000
| New | +$6.62M |
|
16
Icon
ICLR
$13.6B
| $6.19M | 4.22% |
+63,342
| New | +$6.19M |
|
17
Vertex Pharmaceuticals
VRTX
$101B
| $5.95M | 4.06% |
46,202
-33,959
| -42% | -$4.38M |
|
18
Align Technology
ALGN
$9.54B
| $5.09M | 3.47% |
+33,904
| New | +$5.09M |
|
19
Illumina
ILMN
$14.6B
| $4.77M | 3.25% |
+28,270
| New | +$4.77M |
|
20
Intuitive Surgical
ISRG
$161B
| $4.68M | 3.19% |
+45,000
| New | +$4.68M |
|
|
21
Biogen
BIIB
$21.2B
| – | – |
-46,320
| Closed | -$12.7M |
|
|
22
Globus Medical
GMED
$7.93B
| – | – |
-400,000
| Closed | -$11.8M |
|
|
MDRX
23
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-590,000
| Closed | -$7.48M |
|
|
NUVA
24
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-123,317
| Closed | -$9.21M |
|
|
AKRX
25
DELISTED
Akorn, Inc.
AKRX
| – | – |
-300,000
| Closed | -$7.22M |
|